Carnosine Peptide Forms Tunable Hydrogels, Shows Selective Anti-Cancer Action
Background
Peptide hydrogels are emerging as versatile biomaterials for drug delivery and tissue engineering due to their biocompatibility and tunable properties. However, developing peptide-based materials with both controlled physical characteristics and specific biological activity, such as anti-cancer effects, remains a significant challenge. This study addresses the need for novel self-assembling peptide systems that can form tunable hydrogels and exhibit selective toxicity towards cancer cells.
Study Design
Results
The carnosine-derived lipidated peptide (CLP) successfully self-assembled into stable hydrogels, with their mechanical properties being tunable by adjusting peptide concentration and pH. For instance, increasing CLP concentration from 1% to 3% led to a 3-fold increase in hydrogel stiffness. Crucially, CLP demonstrated significant and selective anti-cancer activity in vitro. CLP treatment at a concentration of 100 µM resulted in a >85% reduction in viability for HeLa cancer cells, while showing <15% toxicity to healthy fibroblast cells, indicating high selectivity. Furthermore, CLP induced apoptosis (programmed cell death) in cancer cells, with p<0.01 compared to untreated controls, suggesting a specific mechanism of action. The selectivity ratio (cancer cell IC50 / healthy cell IC50) was found to be >5, highlighting its preferential action against malignant cells.
Why It Matters
This study highlights the potential of carnosine-derived lipidated peptides as a new class of biomaterials with inherent therapeutic properties. The ability to form tunable hydrogels means CLP could serve as a self-delivering anti-cancer agent, potentially improving localized drug delivery and reducing systemic side effects. Such peptides could pave the way for novel, targeted cancer therapies that are both effective and biocompatible. Future steps would involve in vivo studies in animal models to confirm efficacy and safety, followed by preclinical development and potentially Phase I human trials.